Nanoparticles prepared from porcine cells support the healing of cutaneous inflammation in mice and wound re‐epithelialization in human skin

Previous reports have demonstrated that cell‐derived nanoparticles ( CDNP s) composed of bovine or porcine protein complexes exerted therapeutic effects against viral infections and cancer in mice and humans. Based on these observations, we asked whether CDNP s would improve inflammatory skin disorders. To address this, we utilized two distinct mouse models of cutaneous inflammation: the autoimmune skin‐blistering disease epidermolysis bullosa acquisita ( EBA ) as an example of an autoantibody‐induced cutaneous inflammation, and Leishmania major ( L. major ) infection as an example of a pathogen‐induced cutaneous inflammation. In both models, we observed that CDNP s increased mRNA expression of the Th2 cytokine IL ‐4. Clinically, CDNP s decreased inflammation due to EBA and increased L. major ‐specific IgG1 levels without major effects on infected skin lesions. In addition, CDNP s supported the growth of keratinocytes in human skin cultures. In vitro studies revealed that CDNP s were taken up predominantly by macrophages, leading to a shift towards the expression of anti‐inflammatory cytokine genes. Altogether, our data demonstrate that treatment with porcine CDNP s may be a new therapeutic option for the control of autoimmune‐mediated inflammatory skin disorders.